Research on cancer as a disease, from cause to care. Covers tumor biology, small-cell lung cancer, cancer-linked stroke risk, and cancer center research.
A study of 2.9 million Korean adults found that quitting smoking at any age reduced the risk of cancer, particularly lung cancer, after 10 years. Early cessation before middle age led to a substantial risk reduction in lung cancer.
Researchers found that combining SORA with FGF21 increases the sensitivity of SORA to HCC cells under hypoxia conditions. This combination therapy promotes apoptosis and inhibits tumor growth through the PI3K/AKT pathway, suggesting a new potential treatment approach for advanced liver cancer.
The Vilcek Foundation has awarded $250,000 to four immigrant scientists for their pioneering work in biomedical science. Luciano Marraffini, Gerta Hoxhaj, Tomasz Nowakowski, and Takanori Takebe are recognized for their contributions to cancer research, pluripotent stem cells, and CRISPR-Cas systems.
Researchers found that tumors with preexisting immune cell networks were most primed to respond to adoptive T cell therapy, and patients whose tumors featured such networks responded best to treatment. The study provides a step towards identifying patients who are likely to benefit from personalized immunotherapies.
Advanced lung cancer patients treated with combination chemoradiotherapy have a higher incidence of mixed infections and elevated inflammatory markers. Antibiotic therapy is recommended to ensure coverage of gram-negative bacilli pathogens.
Researchers mapped changes in tumor-related bacteria to uncover potential strategies to combat the rise of young-onset colorectal cancer. Unique bacterial signatures were found in tumors from younger patients, including Akkermansia and Bacteroides, which are more likely to have left-sided, rectal, and advanced stage tumors.
Researchers at Michigan State University have found a potential breakthrough in treating glioblastoma by targeting an acid sensor on cancer cell membranes. The compound OGM showed remarkable ability to kill glioblastoma cells while leaving normal cells unharmed.
Scientists have imaged microtubule formation in unprecedented detail, revealing a complex process that involves the gamma-tubulin ring complex and a newly-discovered latch mechanism. The findings hold promise for developing targeted therapies for various diseases, including cancer and neurodevelopmental disorders.
A team of scientists has developed a new type of anticancer agent targeting cancer stem cells, which are difficult to eradicate. The compound, called Ru1, promotes a decrease in the expression of genes necessary for mitochondrial respiration, causing cancerous cells to lose their potential.
Researchers have developed an AI-driven test that accurately diagnoses ovarian cancer in women clinically classified as normal, improving detection of early-stage disease. The test uses machine learning and blood metabolite information to assign a probability of disease presence or absence, offering a more clinically informative approach.
A new CRISPR-based technology, TRED-I, has been developed to increase visibility of cancer cells to the immune system by augmenting MHC class I molecules. This technology has shown promising results in animal cancer models, reducing tumor sizes and enhancing treatment efficacy when used with existing immunotherapy.
Researchers developed a new chip that can detect cancer cells in blood samples, enabling clinicians to adapt treatments and improve outcomes for patients with lung cancer. The device traps and concentrates tiny numbers of cancer cells, allowing for regular monitoring of treatment effectiveness.
Researchers found that the loss of Bmal1 reduces melanoma tumor growth, contrary to expectations. The study also uncovered mechanisms of tumor suppression and resistance to immunotherapy, suggesting a contextually variable role for the circadian clock in cancer.
Researchers discovered that cisplatin chemotherapy enhances the immune system's ability to fight bladder cancer by modulating the immune response and damaging DNA in cancer cells. This approach may lead to durable disease control in a subset of patients with metastatic bladder cancer.
Researchers developed an mRNA therapeutic that combats ovarian cancer by producing functional p53 protein, shrinking and killing tumors. The treatment is effective against metastases and has shown promise in preclinical studies.
A recent survey found that 51% of Americans are unaware that heart disease is the leading cause of death in the US. This lack of knowledge can be deadly, with nearly half of adults having some form of cardiovascular disease.
Senescent tumour cells generated by chemotherapy can create an environment that helps tumour cells escape treatment. Eliminating these cells with immunotherapy boosts the effectiveness of chemotherapy.
A study of 157,000 participants found that those with recent weight loss were more likely to be diagnosed with cancer within the next 12 months. Cancer of the upper gastrointestinal tract was most commonly associated with recent weight loss.
Researchers develop compound that reduces size of kidney cysts and improves kidney function in mouse models of ADPKD. The compound, originally designed to treat cancer, works by exploiting kidney cyst cells' vulnerability to oxidative stress.
Researchers at State University of Campinas discovered genes favoring colossal growth in whales also inhibit cancer development. The study found that certain regulatory regions influence both size and cancer suppression, offering new insights into the evolution of cetacean gigantism.
Stacyann Bailey studies how cancer treatment affects bones, hoping to prevent fractures and improve patient outcomes. Up to 50% of patients with metastatic bone disease develop fractures due to treatment, making her work crucial for their quality of life.
Researchers have revealed CD4+ T cells can work effectively on their own to control melanoma, challenging conventional understanding. Harnessing their potential therapeutically holds great promise for improving current cancer immunotherapies.
A study has generated a detailed portrait of brain tumor blood vessels, revealing how they support cancer growth and immune evasion. Researchers identified a potential target, CD276, and showed that its inhibition extends survival in mice with breast cancer brain metastases.
Researchers developed intravenous priming agents that increase the recovery and detection of tumor-derived genetic fragments in liquid biopsies. In mouse models, these agents increased sensitivity for detecting small tumors from 10% to 75%. The approach may boost the sensitivity of liquid biopsies in cancer care and beyond.
Scientists have developed two injectable priming agents to improve liquid biopsy performance by slowing down the clearance of circulating tumor DNA from the body. In mouse studies, these agents increased circulating tumor DNA levels by more than 10-fold, improving the sensitivity of detecting cancer in mice with low tumor burden.
A groundbreaking study uses machine learning to predict treatment resistance in cervical cancer by analyzing genetic mutations. The algorithm identified molecular assemblies driving treatment resistance and pinpointed tumors most susceptible to therapy, resulting in improved patient outcomes.
A new diagnostic kit allows dentists to screen for oral squamous cell carcinoma with a simple brush biopsy, detecting genetic signals of the disease with over 90% accuracy. The non-invasive test is less complicated than surgical biopsies and can be performed in under a minute without numbing required.
A new study conducted by Qianwei Liu and colleagues found that parents of children with cancer are more likely to attempt suicide during the first years after diagnosis. The risk is higher for parents whose child was diagnosed under 18 or had an aggressive form of cancer.
Researchers have shown that combining poverty with chronic inflammation worsens health outcomes, increasing heart disease and cancer mortality rates. The study analyzed data from nearly 95 million adults and found a synergistic effect of poverty and inflammation on mortality.
Researchers discuss reductive carboxylation of glutamine as a potential target in acute myeloid leukemia (AML), an aggressive cancer with poor patient outcomes. The approach aims to weaken tumor cell survival mechanisms, potentially leading to novel therapies and improved patient outcomes.
Despite declining overall US cancer mortality rates, substantial racial disparities persisted for many common cancers, including breast and colorectal cancer. Structural racism, medical mistrust, and health care access inequities contribute to these disparities.
A study of nearly 15,000 adults with non–small cell lung cancer found that Medicaid expansion decreased postoperative mortality within 30 and 90 days after hospital discharge. This suggests that expanded Medicaid coverage may improve cancer outcomes and access to care for this population.
Adult cancer survivors are at higher risk for substance use disorders (SUD), especially those with certain types of cancer; the study suggests integrated care could benefit these patients. The research highlights the need to address comorbid SUD in cancer populations with high SUD prevalence, prioritizing high-risk cancers.
Researchers at City of Hope have discovered a specific immune cell type that can selectively target and kill cancer cells. The breakthrough could lead to the development of a novel immunotherapy treatment, potentially offering new hope for cancer patients.
Researchers analyzed genome sequences from over 4,000 tumours to identify patterns of DNA mutations that vary between individuals. They found 13 distinct patterns, with 10 corresponding to different types of tissue, and discovered that the density of mutations in specific genes varies significantly between individuals.
The University of Rochester is establishing a new NIH-funded center focused on developing FDA-qualified drug development tools related to barrier functions in disease. Researchers will create microphysiological systems with ultrathin membranes of human cells, aiming to reduce animal trials and improve drug efficacy.
Researchers at Tokyo Medical and Dental University characterize myeloid/natural killer (NK) cell precursor acute leukemia (MNKPL) using multiomics approaches, revealing distinct molecular features. This work provides crucial details for accurate diagnoses and therapeutic decisions.
Researchers developed a deep-learning-based algorithm to identify tissue cellular neighborhoods (TCNs) in breast and colorectal tumors, revealing new fibroblast-enriched and granulocyte-enriched TCNs associated with high-risk disease subtypes. The study aims to better understand cancer evasion mechanisms and potential therapeutic targets.
Researchers created nanoparticles using ultraviolet light crosslinked amino acids, loaded with doxorubicin and coated with tannic acid complex. The nanoparticles exhibited superior stability and drug release under different pH conditions, showing excellent anticancer activity in tumor-bearing mice.
Researchers have found a way to control MYC's hyperactivity using a peptide compound with sub-micro-molar affinity. This breakthrough offers hope for more effective treatments for cancer patients.
A new framework has been established for standardized imaging of diffuse gliomas using amino acid PET, enabling the evaluation of treatment success and improving therapies. The RANO group has developed criteria that enable reliable imaging of tumor activity and extent.
A study in the JAMA Network Open found that Hispanic and American Indian individuals with breast, colorectal, lung, and prostate cancer were undercaptured in the National Cancer Database, but representation improved over time. Further investigation is needed to understand where these populations seek cancer care.
Researchers have made significant progress in understanding the enzyme SMYD3's involvement in prostate cancer's progression to a more aggressive stage. The study found that adding methyl groups to the MAP kinase protein is likely SMYD3's role in driving metastasis, and compounds that can inactivate SMYD3 are already available
Recent review highlights the potential of AGI in radiotherapy, enabling advanced auto-segmentation, tumor staging, and treatment planning. The fusion of vision data with large language models creates powerful multimodal models that elucidate nuanced clinical patterns.
A team of researchers has discovered a new inactive form of the p38a protein, which is regulated by the cellular redox state. This finding opens up new avenues for developing therapeutic compounds that modulate the activity of p38a more precisely.
A team of researchers has identified the allosteric control sites found in the protein KRAS, providing a comprehensive map for controlling its effects. The study offers promising targets for safer and more effective drugs, with potential implications for cancer treatment.
A recent study published in Gastroenterology & Endoscopy found that narrow-band imaging at low magnification can detect lesions missed by white-light imaging. Annual endoscopic examinations using LM-NBI revealed a threefold higher detection rate of neoplastic lesions compared to conventional magnifying endoscopy.
Studies published in Nature Medicine show that implementing updated WHO screening guidelines could reduce cervical cancer death rates by over 63% in low-to-middle-income countries. Women with HIV have a sixfold risk of developing cervical cancer, and primary HPV testing can save up to 38 women's lives for every 71 screened.
A recent study published in The Lancet Oncology found that the risk of dying from cancer in some poorer districts of England is over 70% higher than in wealthier areas. The study used death records to estimate the risk of dying from various cancers in each district, highlighting significant inequalities in cancer mortality across diffe...
Researchers have developed a new model for studying pulmonary neuroendocrine tumors, which may indicate that patients with EGF-dependent NETs can be treated with EGF receptor inhibitors. This discovery provides a promising route of treatment for aggressive pulmonary NETs.
A phase 2 trial PrE0405 showed an 85% complete response rate in 33 patients over 60 with mantle cell lymphoma who received venetoclax combined with bendamustine and rituximab. The combination was generally well-tolerated, with gastrointestinal toxicities common.
Researchers at Université libre de Bruxelles identified a new RNA reader, SRSF2, that plays a key role in the development of leukaemia. The discovery sheds light on a previously unsuspected molecular mechanism leading to leukaemia and may lead to specific diagnoses and new therapeutic approaches.
The University of Texas at Arlington is awarded a $1.1 million grant to train and mentor researchers in mathematical techniques for addressing cancer biology, neurology, and vector-borne diseases. The program aims to increase diversity in science research by recruiting underrepresented scholars.
Researchers leverage AI to analyze healthcare data and identify new targets for effective therapies and accelerate drug development in aging research. AI can tailor cancer treatment more precisely to individual patients' unique aging profiles, optimizing treatment outcomes and minimizing risks.
A study of 562,000 women with endometrial, ovarian, or cervical cancer reveals racial and ethnic disparities in clinical trial enrollment. Underrepresented groups face significant barriers to participation, highlighting the need for continued efforts to address these disparities.
A new method developed at Karolinska Institutet can identify unique immune cell receptors and their location in human tissue. This breakthrough could lead to the development of novel therapies for diseases such as cancer and autoimmune disorders, by pinpointing the specific immune cells responsible.
Researchers at Salk Institute discovered how anti-cancer drugs can prevent fibroblast activation, a protective barrier around pancreatic tumors. The therapy reduces tumor growth and slows disease progression in mice and human patients, offering a promising treatment for pancreatic cancer.
A previously unknown function of the DECTIN-1 protein has been discovered, which exacerbates severe autoimmune diseases in its mutated state. The researchers believe they can control the immune system by turning the protein on and off, offering new treatment options for autoimmune disease and cancer.
Researchers at the Francis Crick Institute have discovered that immune cells use an influx of water and ions to propel themselves forward, a process regulated by the WNK1 protein. This mechanism is essential for T cell migration and has implications for understanding cancer spread.
A recent study from Drexel University's College of Nursing and Health Professions aimed to understand the challenges and supports affecting individuals with GI cancer and their caregivers when it comes to maintaining a healthy diet and avoiding malnutrition. The research highlighted the importance of creating dietary interventions that...